Anticancer phototherapy using activation of E-combretastatins by two-photon–induced isomerization

Abstract. The photoisomerization of relatively nontoxic E-combretastatins to clinically active Z-isomers is shown to occur in solution through both one- and two-photon excitations at 340 and 625 nm, respectively. The photoisomerization is also demonstrated to induce mammalian cell death by a two-photon absorption process at 625 nm. Unlike conventional photodynamic therapy (PDT), the mechanism of photoisomerization is oxygen-independent and active in hypoxic environments such as in tumors. The use of red or near-infrared (NIR) light for two-photon excitation allows greater tissue penetration than conventional UV one-photon excitation. The results provide a baseline for the development of a novel phototherapy that overcomes nondiscriminative systemic toxicity of Z-combretastatins and the limitations of PDT drugs that require the presence of oxygen to promote their activity, with the added benefits of two-photon red or NIR excitation for deeper tissue penetration.

[1]  M. Maynadier,et al.  Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. , 2011, Angewandte Chemie.

[2]  David Kessel,et al.  Photodynamic therapy of cancer: An update , 2011, CA: a cancer journal for clinicians.

[3]  S. Botchway,et al.  Fluorescence lifetime imaging of E-combretastatin uptake and distribution in live mammalian cells. , 2012, European journal of cancer.

[4]  W. Webb,et al.  Multiphoton fluorescence excitation: new spectral windows for biological nonlinear microscopy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Botchway,et al.  Laser-induced radiation microbeam technology and simultaneous real-time fluorescence imaging in live cells. , 2012, Methods in enzymology.

[6]  A. Ustione,et al.  A simple introduction to multiphoton microscopy , 2011, Journal of microscopy.

[7]  S. Botchway,et al.  Spectroscopy and fluorescence lifetime imaging in live cells of a cyano-substituted combretastatin , 2014 .

[8]  K. Flaherty,et al.  Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin , 2005, Clinical Cancer Research.

[9]  H. Kuhn,et al.  Cis‐Trans Photoisomerization of Stilbenes and Stilbene‐Like Molecules , 2007 .

[10]  Mamta Khurana,et al.  Quantitative In Vitro Demonstration of Two‐Photon Photodynamic Therapy Using Photofrin® and Visudyne® , 2007, Photochemistry and photobiology.

[11]  E. Schwartz.  Antivascular Actions of Microtubule-Binding Drugs , 2009, Clinical Cancer Research.

[12]  N. Lawrence,et al.  Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? , 2003, Organic & biomolecular chemistry.

[13]  T. Ganesan,et al.  A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer , 2010, British Journal of Cancer.

[14]  R. Cubeddu,et al.  In vivo optical characterization of human tissues from 610 to 1010 nm by time-resolved reflectance spectroscopy. , 2001, Physics in medicine and biology.

[15]  M. Drobizhev,et al.  Vascular targeting to the SST2 receptor improves the therapeutic response to near-IR two-photon activated PDT for deep-tissue cancer treatment. , 2013, Biochimica et biophysica acta.

[16]  G. Tozer,et al.  Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. , 1997, Cancer research.

[17]  Hazel A. Collins,et al.  Two-photon absorption and the design of two-photon dyes. , 2009, Angewandte Chemie.

[18]  Aleksander Rebane,et al.  Blood-vessel closure using photosensitizers engineered for two-photon excitation , 2008 .

[19]  A. Boulares,et al.  Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. , 1998, Cancer research.

[20]  Aleisha Elliott,et al.  New Two-Photon Activated Photodynamic Therapy Sensitizers Induce Xenograft Tumor Regressions after Near-IR Laser Treatment through the Body of the Host Mouse , 2008, Clinical Cancer Research.

[21]  Kinetics of reversible photoisomerization: determination of the primary quantum yields for the E-Z photoisomerization of silylenephenylenevinylene derivatives. , 2009, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[22]  N. Lawrence,et al.  Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4 , 2003 .

[23]  M. Horsman,et al.  Combretastatin-induced hypertension and the consequences for its combination with other therapies. , 2011, Vascular pharmacology.